SNT 5.00% 3.8¢ syntara limited

time for news, page-9

  1. 1,300 Posts.
    lightbulb Created with Sketch. 69
    guys breathe easy... Spoke to the company regarding the Aridol Phase 3 results. Here are some of the key points to make holders feel a little more comfortable about the results

    - Although the specificity and sensitivity results from the US phase 3 trial are similar it is probable that further analysis of the data will reveal significant differences. In addition the US study was confined to a very specific niche of patients (patients with suspected asthma/ no certain diagnosis). Aridol has applications in a far wider group of patients than this, so one shouldn’t extrapolate the results of this study too far.

    - Aridol is an indirect challenge test and measures a patient’s inflammatory response to an osmotic stimulus. This is very different to a direct challenge test like methacholine which acts directly on the airway smooth muscle.

    - Aridol positive patients have active airway inflammation and are therefore likely to respond to inhaled steroids. The same cannot be said of methacholine.

    - Aridol is thus a more clinically useful test.

    - Aridol offers a standard operating procedure for challenge testing removing the many variables that can effect methacholine testing.

    - Aridol is a faster and cleaner test that both patients and operators will prefer.

    - Aridol has further potential applications in monitoring patient’s response to treatment and managing asthma.
 
watchlist Created with Sketch. Add SNT (ASX) to my watchlist
(20min delay)
Last
3.8¢
Change
-0.002(5.00%)
Mkt cap ! $45.37M
Open High Low Value Volume
4.1¢ 4.1¢ 3.5¢ $92.49K 2.439M

Buyers (Bids)

No. Vol. Price($)
1 15261 3.8¢
 

Sellers (Offers)

Price($) Vol. No.
3.9¢ 33701 1
View Market Depth
Last trade - 15.44pm 19/07/2024 (20 minute delay) ?
SNT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.